Brilaroxazine is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Brilaroxazine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brilaroxazine overview

RP-5063 is under development for the treatment of schizophrenia, schizoaffective disorder, idiopathic pulmonary fibrosis, major depressive disorder, pulmonary arterial hypertension, manic-depressive bipolar disorder, autism spectrum, attention-deficit/hyperactivity disorder and psychosis in Alzheimer’s disease and Parkinson’s diseases. RP-5063 is a new chemical entity and it is administered orally. It targets dopamine D2, D3, D4, 5-HT1A, 5-HT2A, 5-HT2B,5HT2C, 5-HT6 and 5-HT7 receptors. The drug candidate is developed using chemical genomics based technology platform and proprietary chemistries. It was also under development for Tourette syndrome.

Reviva Pharmaceuticals overview

Reviva Pharmaceuticals (Reviva Pharma) is a clinical development pharmaceutical company that develops therapeutic drugs. The company develops drugs in the therapeutic areas of cardiovascular, metabolic, central nervous system and inflammatory diseases. Its product pipeline comprises RP5063 for the treatment of schizophrenia disorders. Reviva Pharma’s product RP5063 is also been developing for Parkinson’s psychosis, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder, Alzheimer’s psychosis and agitation, and autism spectrum. The company also offers clinical trial services. Reviva Pharma is headquartered in Cupertino, California, the US.

For a complete picture of Brilaroxazine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.